Wall Street predicts novavax could soar by 65% is it time to invest novavax NASDAQ nbx has had an impressive year so far with its stock surging by 150% since January but according to analysts the vaccine maker might still have room to grow the consensus Target price of $20 per share suggests a potential 65% increase from its current levels a remarkable turnaround for a company that once faced sign ific Financial struggles so can Nova sustain its momentum and hit this Target in the next 12 months let's dive in key catalysts on the horizon Novac recently signed a partnership with sopi granting sopi the rights to Market no vovid novax's covid-19 vaccine in most countries starting in 2025 until then novax continues its operations as usual recently submitting applications for an updated covid-19 vaccine for the 2024 to 2025 season to regulatory authorities in the US and Europe while the co9 vaccine Market is not as large as it once was and is still dominated by giants like Mna and fiser novavax is poised to generate some Revenue if its updated vaccine gains approval Beyond covid-19 novavax is advancing new vaccines through its Pipeline with plans to initiate phase three trials for a combination covid 19f flu vaccine and a standalone flu vaccine in the fourth quarter results from these studies are expected by mid 2025 just under a year away impact on novax's stock if novax's updated co9 vaccine secures approval it might not cause a significant spike in the stock price as the market has already factored in much of the impact from its partnership with copi however the real potential lies in the upcoming phase three trials success in these trials could significantly boost Nova vax's stock especially since the company currently has no other products on the market approval of these new vaccines could open up new revenue streams potentially driving the stock price Beyond $20 per share the long-term perspective however investing in novax comes with risks the company faces stiff competition in the race to develop a better flu vaccine or a combination flu slco 19 vaccine competing with established players like madna and fizer who have larger product lines and more advanced pipelines raises the stakes for novaa these competitors have already reported mixed results in their late stage trials and if novavax encounters similar challenges it could negatively impact its stock while there's a chance novavax could meet the Market's expectations within the next year there's also a risk that the stock could lose value for investors looking for Less risky opportunities there might be more attractive biotech stocks to consider should you invest in Novac now before jumping into Nova it's worth noting that some top analysts don't see it as one of the best investment opportunities right now the mle full stock advisor team for example has identified other stocks they believe are better positioned to deliver strong returns in the coming years their picks have consistently outperformed the market and their recommendations have helped investors achieve sign ific gains over time for instance those who invested $1,000 in Nvidia when it was recommended by stock advisor in April 2005 with have seen that investment grow to do 792 725 asterisk today if you're looking for a proven strategy to build your portfolio the stock advisor service offers valuable insights regular updates and new stock picks each month having more than quadrupled the return of the SNP 500 since 2002 star asterisk returns as of the time of writing